Also known as: rezpeg, REZPEG
Rezpegaldesleukin (REZPEG/NKTR-358) is a first-in-class regulatory T-cell stimulating biologic in clinical development for autoimmune and inflammatory diseases. Company disclosures describe activity in Phase 2b studies in atopic dermatitis and alopecia areata, with broader development including type 1 diabetes. It remains investigational and not yet marketed.
Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.
Nektar said extended rezpeg treatment promoted greater hair growth in severe alopecia areata and reported durable 52-week efficacy for rezpegaldesleukin in atopic dermatitis. The company said it has FDA alignment on Phase 3 design and is targeting a BLA submission by 2029.
Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07142252 |
Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus |
RECRUITING | PHASE2 |
| NCT06340360 |
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06136741 |
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis |
ACTIVE_NOT_RECRUITING | PHASE2 |
